Lucius LuciVibe Vibegron 75mg

Product Information

• Product name: LuciVibe Vibegron 75mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Vibegron
• Current strength: 75mg
• SKU: LU-ITEM-126
• Site category: other cancer

Product Summary

LuciVibe Vibegron 75mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Vibegron is the active ingredient used for this product page. Public prescribing information for Vibegron was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Vibegron is a selective human beta-3 adrenergic receptor agonist. Activation of the beta-3 adrenergic receptor increases bladder capacity by relaxing the detrusor smooth muscle during bladder filling.

Reference Indications

Vibegron is a beta-3 adrenergic agonist indicated for the treatment of: overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH).

Reference Dosage and Administration

Recommended dose is one 75 mg tablet orally once daily. Swallow tablet whole with water.

With this 75mg product, that corresponds to 1 x 75mg tablet when that reference dose is clinically appropriate.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

Urinary Retention : Monitor for urinary retention, especially in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for OAB, in whom the risk of urinary retention may be greater. If urinary retention develops, discontinue Vibegron. Angioedema : Angioedema of the face and/or larynx has been reported with Vibegron. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for the treatment of OAB. Monitor patients for signs and symptoms of urinary retention, particularly in patients with bladder outlet obstruction or patients taking muscarinic antagonist medications for the treatment of OAB. Discontinue Vibegron in patients who develop urinary retention .

Common Adverse Reactions and Monitoring

Overactive Bladder in Adults The safety of Vibegron was evaluated in a 12-week, double-blind, placebo- and active-controlled study (Study 3003) in patients with OAB . A total of 545 patients received Vibegron. The majority of the patients were White (78%) and female (85%) with a mean age of 60 years (range 18 to 93 years). Overactive Bladder in Adult Males with BPH The safety of Vibegron was evaluated in a 24-week double-blind, randomized, placebo-controlled study (Study 3005) in male patients with OAB on pharmacological therapy for BPH. A total of 553 patients received Vibegron .

Drug Interactions and Special Populations

Concomitant use of Vibegron increases digoxin maximal concentrations (C max ) and systemic exposure as assessed by area under the concentration-time curve (AUC) . Serum digoxin concentrations should be monitored before initiating and during therapy with Vibegron and used for titration of the digoxin dose to obtain the desired clinical effect. Continue monitoring digoxin concentrations upon discontinuation of Vibegron and adjust digoxin dose as needed. Digoxin : Measure serum digoxin concentrations before initiating Vibegron. Monitor serum digoxin concentrations to titrate digoxin dose to desired clinical effect. Pediatric use : Safety and effectiveness in pediatric patients have not been established. End-stage Renal Disease with or without Hemodialysis : Not recommended. Severe Hepatic Impairment : Not recommended.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: GEMTESA public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.